Editas Medicine EDIT 深 沪
已收盘 10-09 16:00:00 美东时间
2.90
+0.060
+2.11%
华盛通- 最 高2.97
- 今 开2.85
- 成交量 308.75万股
- 最 低 2.71
- 昨 收 2.84
- 总市值 4.45亿
- 52周最高 4.275
- 市盈率 静 --
- 换手率 2.01%
- 52周最低 1.66
- 委 比 -55.67%
- 总股本 1.54亿
- 历史最高 99.95
- 量 比 0.94
- 振 幅 9.15%
- 历史最低 0.9101
- 每 手 1
- 风险率 0.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅179.23%！奥本海默上调Aurora Innovation目标价至16美元，维持"跑赢大市"评级
今日重点评级关注：奥本海默：维持Aurora Innovation"跑赢大市"评级，目标价从15美元升至16美元；富国银行：维持Applied Digital"超配"评级，目标价从50美元升至55美元
10-09 16:25
Editas Medicine Receives Approval To Initiate Its Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In Australia
The trial has received Human Research Ethics Committee (HREC) approval and completed the Clinical Trial Notification (CTN) process with Australia’s Therapeutic Goods Administration (TGA) and has also been submitted for review in New Zealand. If approved in New Zealand, patients in both countries wil...
10-08 19:18
美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
Anthropic IPO前亮科研牌：Claude“自主发现”类CRISPR系统，基因编辑板块遭遇“AI替代焦虑”
周三，美股基因编辑公司股价走低。此前，Anthropic宣布，其AI模型Claude“自主发现”了一种类似于基因编辑工具CRISPR的新型酶系统。 个股方面，...
09-24 07:21
Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target
Guggenheim analyst Debjit Chattopadhyay upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and announces $5 price target.
09-23 20:29
Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket
Shares of Veea Inc (NASDAQ:VEEA) rose sharply in pre-market trading after the company announced a potential merger with NovaGen Group B.V. and a $10 million cornerstone investment from GeoNova Capital. Veea and NovaGen signed a term sheet to combine and are targeting execution of a definitive busine...
09-15 17:18
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Editas Medicine appoints Dan Ory, M.D., as Chief Medical Officer. With over 25 years of experience in cardiovascular and genetic medicine, Ory will oversee clinical development, particularly for EDIT-401, a potential treatment for hyperlipidemia. Ory previously led clinical programs at Arbor Biotechnologies and Casma Therapeutics and conducted research at Washington University School of Medicine. His expertise strengthens Editas' mission to advan...
09-08 11:00
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine, a gene-editing company, announced it will participate in two investor conferences in September. The first is the Wells Fargo Healthcare Conference on September 8 in Boston, and the second is the 2026 Cantor Global Healthcare Conference on September 10 in New York. Both events will feature Fireside Chat formats. Live webcasts and replays will be available on the company’s website. Editas Medicine focuses on developing CRISPR-based...
09-01 13:00
Editas Medicine Files Prospectus For Offering $400M Mixed Shelf
Editas Medicine Files Prospectus For Offering $400M Mixed Shelf
09-01 04:28
Moderna(MRNA.US)mRNA癌症疫苗重大突破引爆市场情绪！生物科技板块估值重估可能才刚开始
生物科技行业在很大程度上受到临床事件的驱动——一项三期临床试验的成功或失败，不仅可以推动直接参与其中的公司股价大幅波动，也可能影响它们所代表的整个治疗技术类别...
08-25 11:45
